Table of contents

• Trial overview
• Studied populations
• Trial designs and phases
• Main outcomes measured
• What the studies compare
• What the results mean for patients

Trial overview

These studies investigate vaccines that include MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED) as part of combined vaccination programs.^[1] The trials focus on immune response and safety in children, not on treating an active illness.^[1][2]

Two trials are listed here.^{[1][2] One is a Phase 3 study in healthy children 12 to 15 months of age, and the other is a Phase 2 study in healthy children 4 to 6 years of age.[1][2]}

Studied populations

The first trial includes healthy children 12 to 15 months old and studies varicella prevention together with measles, mumps, and rubella vaccination.^[1] The second trial includes healthy children 4 to 6 years old and evaluates a combined measles, mumps, rubella, and varicella vaccine.^[2]

• Healthy children 12 to 15 months of age: this group is used to see how well the vaccine response develops at the usual early childhood vaccination age.^[1]
• Healthy children 4 to 6 years of age: this group helps researchers compare immune response in older children who receive combined vaccine schedules.^[2]

Trial designs and phases

Both studies are interventional, which means researchers give a vaccine and then measure the results.^{[1][2] The Phase 3 trial uses a larger group of children, while the Phase 2 trial is focused on immune response testing in a smaller development stage.[1][2]}

The Phase 3 study compares intramuscular administration of the investigational vaccine with subcutaneous administration of a marketed comparator vaccine.^[1] The Phase 2 study compares different potencies of the combined vaccine with a marketed combined vaccine.^[2]

• Interventional: the trial team gives the vaccine to study participants and then observes the immune response.^[1][2]
• Non-inferiority: a test to show that one vaccine is not worse than another by more than a small, set amount.^[1]
• Comparator vaccine: the vaccine used as the reference point for comparison in the study.^[1][2]

Main outcomes measured

The main outcomes in these trials are immune response measures taken at Day 43 after vaccination.^{[1][2] Researchers measure seroresponse and antibody concentrations for measles, mumps, rubella, and varicella-related antigens.[1][2]}

• Seroresponse to VZV gE: checks whether the body makes a clear immune response to varicella zoster virus glycoprotein E at Day 43.^[1]
• Anti-VZV gE IgG concentration: measures the level of IgG antibodies, a type of protective antibody, against varicella zoster virus glycoprotein E.^[1]
• Seroresponse to MMR antigens: checks immune response to measles, mumps, and rubella parts of the vaccine.^[1]
• Anti-measles, anti-mumps, and anti-rubella IgG concentration: measures the amount of these antibodies in the blood after vaccination.^[1]
• Geometric mean concentration (GMC): the average antibody level used to compare groups in the study.^[2]

In the Phase 2 trial, the primary outcomes are anti-measles, anti-mumps, anti-rubella, and anti-glycoprotein E antibody geometric mean concentrations at Day 43.^[2] In the Phase 3 trial, the main focus is whether the immune response after intramuscular use is not inferior to the subcutaneous route.^[1]

What the studies compare

The Phase 3 trial compares an investigational chickenpox vaccine given by intramuscular injection with a marketed varicella vaccine given under the skin, and it also compares intramuscular and subcutaneous use of the combined measles, mumps, and rubella vaccine.^[1] This helps researchers see whether the new way of giving the vaccine gives a similar immune response.^[1]

The Phase 2 trial compares combined vaccines with different potencies against a marketed combined vaccine.^[2] The goal is to evaluate the immune response to measles, mumps, rubella, and varicella components in a controlled research setting.^[2]

• Intramuscular injection: vaccine given into a muscle.^[1]
• Subcutaneous use: vaccine given under the skin.^[1]
• Potency: the strength of a vaccine preparation used in the study.^[2]

What the results mean for patients

For families, these trials are mainly about learning whether combined childhood vaccines produce a strong immune response and whether different ways of giving them work well.^{[1][2] The trials do not report treatment of disease; they are preventive vaccine studies in healthy children.[1][2]}

The information collected may help researchers decide whether a vaccine schedule is effective enough to move forward in development or use in children.^{[1][2] The key question is whether the vaccine creates the expected antibody response after vaccination.[1][2]}